Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients

Bibliography

• UNAIDS. AIDS epidemic update: November 2009. 2009
   Google Scholar
• Szczech LA, Gange SJ, van der Horst C, Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002;61:195-202
   PubMed Web of Science ®Google Scholar
• Gupta SK, Mamlin BW, Johnson CS, Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004;61:1-6
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Winston JA, Malvestutto CD, Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007;21:2101-3
   PubMed Web of Science ®Google Scholar
• Mulenga LB, Kruse G, Lakhi S, Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008;22:1821-7
   PubMed Web of Science ®Google Scholar
• Gardner LI, Holmberg SD, Williamson JM, Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003;32:203-9
   PubMed Web of Science ®Google Scholar
• Szczech LA, Hoover DR, Feldman JG, Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004;39:1199-206
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Hoover DR, Shi Q, Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr 2010;55:73-7
   PubMedGoogle Scholar
• D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998;18:406-21
   PubMed Web of Science ®Google Scholar
• Rao TK, Filippone EJ, Nicastri AD, Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669-73
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, ; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 2002;13:2997-3004
   PubMed Web of Science ®Google Scholar
• USRDS. USRDS 2009 Annual Data Report. 2009
   Google Scholar
• Shahinian V, Rajaraman S, Borucki M, Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000;35:884-8
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Morgello S, Katz-Malamed R, The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009;75:428-34
   PubMed Web of Science ®Google Scholar
• Han TM, Naicker S, Ramdial PK, A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006;69:2243-50
   PubMed Web of Science ®Google Scholar
• Berliner AR, Fine DM, Lucas GM, Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008;28:478-86
   PubMed Web of Science ®Google Scholar
• Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000;14:637-45
   PubMed Web of Science ®Google Scholar
• Fine DM, Perazella MA, Lucas GM, Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis 2008;51:504-14
   PubMed Web of Science ®Google Scholar
• Izzedine H, Deray G. The nephrologist in the HAART era. AIDS 2007;21:409-21
   PubMed Web of Science ®Google Scholar
• Szczech LA, Gupta SK, Habash R, The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004;66:1145-52
   PubMed Web of Science ®Google Scholar
• Nochy D, Glotz D, Dosquet P, Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993;8:11-19
   PubMed Web of Science ®Google Scholar
• Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl 2003;83:S43-9
   Google Scholar
• Leventhal JS, Ross MJ. Pathogenesis of HIV-associated nephropathy. Semin Nephrol 2008;28:523-34
   PubMedGoogle Scholar
• Freedman BI, Soucie JM, Stone SM, Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999;34:254-8
   PubMed Web of Science ®Google Scholar
• Kao WH, Klag MJ, Meoni LA, MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185-92
   PubMed Web of Science ®Google Scholar
• Kopp JB, Smith MW, Nelson GW, MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175-84
   PubMed Web of Science ®Google Scholar
• Dong F, Li S, Pujol-Moix N, Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005;130:620-7
   PubMed Web of Science ®Google Scholar
• Genovese G, Friedman DJ, Ross MD, Association of trypanolytic ApoL1 variants with kidney disease in African-Americans. Science 2010;329:841-5
   PubMed Web of Science ®Google Scholar
• Tzur S, Rosset S, Shemer R, Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010;128:345-50
   PubMed Web of Science ®Google Scholar
• Gupta SK, Eustace JA, Winston JA, Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJJ, Reiss P, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70
   PubMed Web of Science ®Google Scholar
• Ifudu O, Rao TK, Tan CC, Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995;15:217-21
   PubMedGoogle Scholar
• Wali RK, Drachenberg CI, Papadimitriou JC, HIV-1-associated nephropathy and response to highly-active antiretroviral therapy [letter]. Lancet 1998;352:783-4
   PubMed Web of Science ®Google Scholar
• Winston JA, Bruggeman LA, Ross MD, Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001;344:1979-84
   PubMed Web of Science ®Google Scholar
• Szczech LA, Edwards LJ, Sanders LL, Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002;57:336-41
   PubMed Web of Science ®Google Scholar
• Atta MG, Gallant JE, Rahman MH, Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006;21:2809-13
   PubMed Web of Science ®Google Scholar
• Lucas GM, Eustace JA, Sozio S, Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004;18:541-46
   PubMed Web of Science ®Google Scholar
• Schwartz EJ, Szczech LA, Ross MJ, Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005;16:2412-20
   PubMed Web of Science ®Google Scholar
• Yahaya I, Uthman AO, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev 2009:CD007183
   Google Scholar
• Smith MC, Austen JL, Carey JT, Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996;101:41-8
   PubMed Web of Science ®Google Scholar
• Eustace JA, Nuermberger E, Choi M, Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000;58:1253-60
   PubMed Web of Science ®Google Scholar
• Laradi A, Mallet A, Beaufils H, HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France. J Am Soc Nephrol 1998;9:2327-35
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26
   PubMed Web of Science ®Google Scholar
• Jones DW, Hall JE. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials. Hypertension 2004;43:1-3
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996;28:202-8
   PubMed Web of Science ®Google Scholar
• Burns GC, Paul SK, Toth IR, Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997;8:1140-46
   PubMed Web of Science ®Google Scholar
• Wei A, Burns GC, Williams BA, Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003;64:1462-71
   PubMed Web of Science ®Google Scholar
• Szczech LA, Winston JA. The impact of antiretroviral therapy on HIVAN. Kidney Int 2004;65:1114; author reply 1115
   PubMedGoogle Scholar
• Ingulli E, Tejani A, Fikrig S, Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 1991;119:710-16
   PubMed Web of Science ®Google Scholar
• Reid A, Stohr W, Walker AS, Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008;46:1271-81
   PubMed Web of Science ®Google Scholar
• Peters PJ, Moore DM, Mermin J, Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 2008;74:845-7
   PubMedGoogle Scholar
• Kalayjian RC, Franceschini N, Gupta SK, Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008;22:481-7
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Scherzer R, Bacchetti P, HIV viremia and changes in kidney function. AIDS 2009;23:1089-96
   PubMed Web of Science ®Google Scholar
• Mocroft A, Wyatt C, Szczech L, Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009;23:71-82
   PubMed Web of Science ®Google Scholar
• Rachakonda AK, Kimmel PL. CKD in HIV-infected patients other than HIV-associated nephropathy. Adv Chronic Kidney Dis 2010;17:83-93
   PubMedGoogle Scholar
• Gorriz JL, Rovira E, Sancho A, IgA nephropathy associated with human immuno deficiency virus infection: antiproteinuric effect of captopril. Nephrol Dial Transplant 1997;12:2796-7
   PubMedGoogle Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009; 1-161. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 21 October 2010]
   Google Scholar
• Ray AS, Cihlar T, Robinson KL, Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297-304
   PubMed Web of Science ®Google Scholar
• Ortiz A, Justo P, Sanz A, Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther 2005;10:185-90
   PubMed Web of Science ®Google Scholar
• Bendele RA, Richardson FC. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum Pathol 2002;33:574
   PubMed Web of Science ®Google Scholar
• Gitman MD, Hirschwerk D, Baskin CH, Tenofovir-induced kidney injury. Expert Opin Drug Saf 2007;6:155-64
   PubMed Web of Science ®Google Scholar
• Nelson MR, Katlama C, Montaner JS, The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273-81
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-78
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8
   PubMed Web of Science ®Google Scholar
• Young B, Buchacz K, Baker RK, Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:178-87
   PubMedGoogle Scholar
• Fux CA, Simcock M, Wolbers M, Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12:1165-73
   PubMed Web of Science ®Google Scholar
• Winston A, Amin J, Mallon P, Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006;7:105-11
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-8
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009;23:1971-5
   PubMed Web of Science ®Google Scholar
• Parsonage MJ, Wilkins EG, Snowden N, The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005;6:341-6
   PubMed Web of Science ®Google Scholar
• Gagnon RF, Tecimer SN, Watters AK, Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000;36:507-15
   PubMed Web of Science ®Google Scholar
• Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010;17:72-82
   PubMed Web of Science ®Google Scholar
• Kopp JB, Miller KD, Mican JA, Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25
   PubMed Web of Science ®Google Scholar
• Dieleman JP, Sturkenboom MC, Jambroes M, Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002;162:1493-501
   PubMed Web of Science ®Google Scholar
• Kopp JB, Falloon J, Filie A, Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002;34:1122-8
   PubMed Web of Science ®Google Scholar
• Chan-Tack KM, Truffa MM, Struble KA, Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007;21:1215-18
   PubMed Web of Science ®Google Scholar
• Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004;44:e81-4
   PubMed Web of Science ®Google Scholar
• Izzedine H, M'rad MB, Bardier A, Atazanavir crystal nephropathy. AIDS 2007;21:2357-58
   PubMed Web of Science ®Google Scholar
• Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 2006;52:296-7
   PubMed Web of Science ®Google Scholar
• Krishnan M, Nair R, Haas M, Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 2000;36:1075-8
   PubMed Web of Science ®Google Scholar
• Crowther MA, Callaghan W, Hodsman AB, Dideoxyinosine-associated nephrotoxicity. AIDS 1993;7:131-2
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 2005;19:844-5
   PubMed Web of Science ®Google Scholar
• Nelson M, Azwa A, Sokwala A, Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008;22:1374-6
   PubMed Web of Science ®Google Scholar
• Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 2001;15:140-1
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Brignolo LL, Meyer DJ, Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004;48:1469-87
   PubMed Web of Science ®Google Scholar
• Judd A, Boyd KL, Stohr W, Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010;24:525-34
   PubMed Web of Science ®Google Scholar
• Angel-Moreno-Maroto A, Suarez-Castellano L, Hernandez-Cabrera M, Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect 2006;52:e39-40
   PubMedGoogle Scholar
• Barbour TD, Furlong TJ, Finlayson RJ. Efavirenz-associated podocyte damage. AIDS 2007;21:257-8
   PubMedGoogle Scholar
• Wirth GJ, Teuscher J, Graf JD, Efavirenz-induced urolithiasis. Urol Res 2006;34:288-9
   PubMed Web of Science ®Google Scholar
• Curry E, Thomas M, Yehia M. Renal impairment and hypersensitivity reaction due to efavirenz. Nephrology (Carlton) 2008;13:541
   PubMedGoogle Scholar
• Knudtson E, Para M, Boswell H, Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol 2003;101:1094-7
   PubMed Web of Science ®Google Scholar
• Feicke A, Rentsch KM, Oertle D, Same patient, new stone composition: amprenavir urinary stone. Antivir Ther 2008;13:733-34
   PubMedGoogle Scholar
• Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 1999;340:392-3
   PubMed Web of Science ®Google Scholar
• Iba-Ba J, Yombi JC, Danse E, Bilateral papillary necrosis during indinavir treatment. Presse Med 2008;37:967-9
   PubMedGoogle Scholar
• van Rossum AM, Dieleman JP, Fraaij PL, Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics 2002;110:e19
   PubMed Web of Science ®Google Scholar
• Stricker RB, Man KM, Bouvier DB, Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997;349:1745-6
   PubMed Web of Science ®Google Scholar
• Doco-Lecompte T, Garrec A, Thomas L, Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004;18:705-6
   PubMed Web of Science ®Google Scholar
• Engeler DS, John H, Rentsch KM, Nelfinavir urinary stones. J Urol 2002;167:1384-5
   PubMed Web of Science ®Google Scholar
• Green ST, McKendrick MW, Schmid ML, Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS 1998;9:555
   PubMed Web of Science ®Google Scholar
• Zhang X, Lalezari JP, Badley AD, Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004;75:558-68
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
   PubMed Web of Science ®Google Scholar
• Gulick RM, Su Z, Flexner C, Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
   PubMed Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5
   PubMed Web of Science ®Google Scholar
• Parkhie SM, Fine DM, Lucas GM, Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 2010
   Google Scholar
• De Vriese AS, Robbrecht DL, Vanholder RC, Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 1998;31:108-15
   PubMed Web of Science ®Google Scholar
• de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002;6:622-7
   PubMed Web of Science ®Google Scholar
• Wingard JR, Kubilis P, Lee L, Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-07
   PubMed Web of Science ®Google Scholar
• Becker BN, Fall P, Hall C, Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 1993;22:611-15
   PubMed Web of Science ®Google Scholar
• Sawyer MH, Webb DE, Balow JE, Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988;84:1067-71
   PubMed Web of Science ®Google Scholar
• Ha NB, Garcia RT, Trinh HN, Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34
   PubMed Web of Science ®Google Scholar
• Ljungman P, Deliliers GL, Platzbecker U, Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388-92
   PubMed Web of Science ®Google Scholar
• Maurice-Estepa L, Daudon M, Katlama C, Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998;32:392-400
   PubMed Web of Science ®Google Scholar
• Navarro JF, Quereda C, Gallego N, Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996;27:431-4
   PubMed Web of Science ®Google Scholar
• Schmidt GM, Horak DA, Niland JC, A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991;324:1005-11
   PubMed Web of Science ®Google Scholar